Microplasmin looks promising for the treatment of vitreomacular traction

Article

ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.

ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.

The MIVI IIT trial is a Phase IIa, sham injection controlled, dose ascending (75, 125 µg) trial, which has recruited 30 patients in Europe. While the study remains masked, preliminary data demonstrates that microplasmin was well tolerated in both treatment groups and furthermore, posterior vitreous detachment (PVD) was seen in a number of patients and in some cases led to the non-surgical resolution of traction.

Unmasked results of the study will be presented later this year at the American Society of Retina Specialists annual meeting in California, US.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.